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Identity 
Other names: IL-21, IL-22, IL-D110, IL-TIF, IL21, 
ILTIF, MGC79382, MGC79384, TIFIL-23, TIFa, 
zcyto18 




The gene spans a region of 5.2 kb and the coding part is 
divided into five exons. 
Transcription 
Only one type of transcript has been described. The 
540-nucleotide transcript encodes a protein of 179 
amino acid residues. The first and last exons are 
partially untranslated. 
Pseudogene 
None described so far. 
Protein 
Description 
IL-22 is a cytokine composed of 179 residues. 
 
 
Representation of the IL22 gene organization. Interleukin 22 gene and RNA structure. 
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Crystal structure of IL-22 at 2.6 A resolution. Adapted from 
PDB (access number: 1YKB). 
Expression 
Interleukin 22 (IL-22) is a cytokine that was originally 
labeled IL-10-related T-cell-derived inducible factor. 
IL-22 belongs to a family of IL-10-related proteins that 
includes IL-19, IL-20, IL-24/MDA-7, IL-26/AK155, 
IL-28 and IL-29. IL-22 production is inducible by IL-9 
in T-lymphocytes and is known to exert its function by 
binding to a heterodimeric receptor complex composed 
of IL-22R1 and IL-10R2. However, more recently, it 
has been shown that IL-22 can bind the homodimeric 
receptor composed of the IL-22RA1 chain. IL-22 is 
normally produced by natural killer cells and Th-17 T 
cells, a functional distinct population of human helper 
T cells recently identified as an important source of IL-
22. 
Localisation 
IL-22 is a secreted protein. 
Function 
IL-22 exerts its biological effects through the IL-22 
receptor/signaling complex, which expression is largely 
restricted to epithelial cells. Activation of this complex 
leads to the activation of various cellular signalig 
pathways, with the JAK/STAT and MAPK pathways 
being the best characterized. IL-22, as a Th1 cytokine, 
has been shown to play important roles in mediating 
inflammation and the wound healing process. 
Mutations 
Note 
No mutation has been reported thus far. 
Implicated in 
ALK-positive anaplastic large cell 
lymphoma (ALK+ALCL) 
Disease 
Anaplastic lymphoma kinase (ALK)-positive anaplastic 
large-cell lymphoma (ALCL), or ALK+ALCL, is a 
specific type of non-Hodgkin lymphoma characterized 
by the T/null-cell immunophenotype, consistent 
expression of CD30 and reciprocal chromosomal 
translocations involving the ALK gene. In most cases, 
the chromosomal translocation is that of the 
t(2;5)(p23;q35) type, which leads to the juxtapositi n 
of the nucleophosmin (NPM) gene at 5q35 to the ALK 
gene at 2p23. Mounting evidence suggests that the 
resulting oncogenic fusion protein, NPM-ALK, plays 
crucial roles in the pathogenesis of these tumors. 
Patients with ALK+ALCL are typically treated with 
combination chemotherapy containing doxorubicin. 
ALK+ALCL represents the second most common 
pediatric lymphoid cancer. The prognosis of pediatric 
patients is far better than that of adult patients. 
Dien Bard et al. have shown that IL-22 secreted by 
ALK+ALCL lymphoma cells stimulates STAT3 
activation and the growth of these cells. Blocking the
IL-22 signaling pathway using an IL-22-neutralizing 
antibody has been shown to significantly decrease the 
growth of ALK+ALCL cells in-vitro. 
Cytogenetics 
t(2;5)(p23;q35) in most ALK+ALCL patients; other 





ALK negative anaplastic large cell 
lymphoma (ALK-ALCL) 
Disease 
ALK-ALCL is a subtype of ALCL characterized by a 
strong and homogeneous expression of CD30. These 
cells don't express the ALK protein. ALK-ALCL has a 
less favourable prognosis than ALK+ALCL. Patients 
with ALK-ALCL are usually older than in 
ALK+ALCL, 58 versus 34 years, and present a male 
predominance. Patients are treated with standard CHOP 
(cyclophosphamide, hydroxydaunorubicin, vincristine, 
prednisone) chemotherapy. By subtractive genomic 
hybridization, Lamant et al. have identified that IL-22 
transcript is over-expressed in ALK-ALCL when 
compared to ALK+ALCL. However, the authors did 




There are two major types of lung cancer. The non-
small cell lung cancer (NSCLC) is the most common 
type of lung cancer and is divided into three major 
subtypes: squamous cell carcinoma, adenocarcinoma 
and large cell carcinoma. Small cell lung cancer 
represents the second type of lung cancer and is also 
subdivided in three different subgroups: small cell 
carcinoma, mixed small cell/large cell and combined 
small cell carcinoma. More than 90% of lung cancers in 






Atlas Genet Cytogenet Oncol Haematol. 2011; 15(2)  189 
men, and at least 70% in women are directly caused by 
cigarette smoking. Treatment is dependent on the lung
cancer type and may involve surgery, radiation therapy 
and chemotherapy. The overall survival after 5 years 
for men and women is less than 20%. Evidence from 
both in vivo and in vitro experiments implicates IL-22 
as a player in the development of non-small cell lung 
carcinoma (NSCLC) (Zhang et al., 2008). The authors 
have demonstrated that NSCLC patients have high 
levels of IL-22 protein in their serum when compared 
to normal individuals. Moreover, in NSCLC cells 
exogenous addition of recombinant IL-22 cytokine 
induces pro-survival pathways, including STAT3 
signaling, and increase cell proliferation. They have 
also showed that IL-22 protects cancer cells from 
serum starvation and chemotherapeutic drug-induced 
apoptosis. In a xenograft model of NSCLC they have 
showed that down-regulation of IL-22 production 
significantly decreases the volume of the lung tumors. 
Vitiligo 
Disease 
Vitiligo is characterized by the loss skin pigmentation. 
It's a multifactorial and polygenic disease. There a
two forms of vitiligo, the segmental and the non-
segmental form that are related to the pattern of the 
lesion. The disease affects both men and women. 
Vitiligo has been associated with autoimmune and 
inflammatory disorders, but the exact origin and causes 
are unknown. There is no cure for vitiligo to date, but 
treatment is available to slow down the depigmentation. 
In a recent study by Rätsep et al., it has been 
demonstrated that IL-22 mRNA and protein levels are 
associated with the disease. The authors have suggeted 
that IL-22 may induce the inflammation process at the 




Recently, Ma et al. have demonstrated in a mouse 
model of psoriasis, that IL-22 is a key player in the 
development of this disease. Antibodies that 
neutralized IL-22 were found to prevent the 
development of psoriasis-like disease, reducing 
thickening of the skin, inflammatory infiltrates, and 
expression of Th17 cytokines. On the other hand, 
injection of IL-22 into the skin of normal mice induced 
the expression of genes associated with the 
development of psoriasis-like lesions. These data hve 
revealed a new and promising approach for the 
treatment of psoriasis by antagonizing IL-22 activity. 
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